Uterine Fibroids Treatment Devices Market

• The leading Uterine Fibroids Treatment Devices companies working in the Uterine Fibroids Treatment Devices Market include Hologic, Inc., Merit Medical Systems, Insightec, Boston Scientific Corporation, Profound Medical, Olympus Corporation, Medtronic, Intuitive Surgical, KARL STORZ, Cook, The Cooper Companies Inc., Terumo Corporation, Stryker, CONMED Corporation, Minerva Surgical, Inc., Smith+Nephew, Momentis Innovative Surgery, Asensus Surgical US, Inc., Koninklijke Philips N.V., Johnson & Johnson Services, Inc., and others.
• According to data from NHS UK (2022), around two in three women develop at least one fibroid at some point in their life. They mostly occur in women aged 30 to 50.

Uterine Fibroids Treatment Devices Market by Product (Instruments and Consumables), Uterine Fibroids Treatment Devices Market by Procedure (Invasive, and Minimally Invasive {Laparoscopic Radiofrequency Ablation, Ultrasound Radiofrequency Ablation, Robotic-assisted Surgery, and Others), Uterine Fibroids Treatment Devices Market by End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Uterine Fibroids Treatment Devices Market by Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing cases of uterine fibroids, increased awareness and early diagnosis, increased in technological advancement, and increase in product development activities among the key Uterine Fibroids Treatment Devices companies.

The global uterine fibroids treatment devices market is estimated to grow at a CAGR of 8.57% during the forecast period from 2025 to 2032. The demand for uterine fibroids treatment devices is being driven by the increasing cases of uterine fibroids, particularly among women of reproductive age, which is generating strong demand for effective treatment options. Simultaneously, greater awareness about the condition and improved access to healthcare are leading to earlier diagnosis, prompting timely medical intervention. Technological advancements have enabled the development of minimally invasive and more efficient treatment devices, enhancing patient outcomes and reducing recovery times. Furthermore, leading Uterine Fibroids Treatment Devices companies are actively investing in product development, introducing innovative solutions such as advanced ablation systems and robotic-assisted surgical tools. These factors collectively position the uterine fibroids treatment devices market for positive growth throughout the forecast period from 2025 to 2032.

Uterine Fibroids Treatment Devices Market Dynamics:

According to data from NHS UK (2022), around two in three women develop at least one fibroid at some point in their life. They mostly occur in women aged 30 to 50. The high prevalence of uterine fibroids, especially among women aged 30 to 50, is driving strong demand for effective Uterine Fibroids Treatment Devices treatment options. As more women become health-conscious and proactive about managing gynecological issues like heavy bleeding, pelvic pain, and infertility, the rate of diagnosis and treatment increases. This, in turn, boosts the market for uterine fibroids treatment devices, as healthcare providers increasingly adopt advanced, minimally invasive solutions such as laparoscopic tools, radiofrequency ablation systems, and MRI-guided therapies to meet patient needs and preserve fertility.

Additionally, hysterectomies, which involve the surgical removal of the uterus, are one of the most common and definitive treatment options for women with severe or recurrent uterine fibroids. The increasing number of hysterectomies performed globally, particularly due to complications such as chronic pain, heavy menstrual bleeding, or significant pressure symptoms caused by large or multiple fibroids, is significantly boosting the market for uterine fibroids treatment devices. NHS England (2024), reports that more than 1,000 hysterectomies were performed weekly in the UK, highlighting the widespread demand for fibroid treatments. These procedures often require advanced surgical tools, including electrosurgical devices and laparoscopic or robotic-assisted instruments, to ensure precision, safety, and minimally invasive access thereby boosting the overall market of uterine fibroids treatment devices.

Moreover, technological advancements and product development further support this trend. For instance, in March 2024, Intuitive Surgical, a global leader in minimally invasive technology and pioneer in robotic-assisted surgery, announced that its next-generation multiport robotic system, Da Vinci 5, received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This advanced system incorporates significant enhancements, such as improved precision through advanced surgeon controllers, next-generation 3D imaging, and the introduction of Force Feedback technology, allowing surgeons to feel subtle forces on tissue to reduce trauma. Additionally, Da Vinci 5 optimizes workflow with integrated OR technologies, enhanced computing capabilities, and a redesigned console that improves surgeon comfort and efficiency.

However, the safety and complications associated with invasive surgical procedures of fibroids treatment and high treatment costs, among others are some of the key constraints that may limit the growth of the uterine fibroids treatment devices market.

Uterine Fibroids Treatment Devices Market Segment Analysis:

Uterine Fibroids Treatment Devices Market by Product (Instruments and Consumables), Procedure (Invasive, and Minimally Invasive {Laparoscopic Radiofrequency Ablation, Ultrasound Radiofrequency Ablation, Robotic-assisted Surgery, and Others}), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product segment of the uterine fibroids treatment devices market, the instruments category is estimated to account for the largest market share in 2023. This can be attributed to the various advantages and applications provided by the instrument used in uterine fibroids treatment. Uterine fibroid treatment instruments offer a range of advantages that make them ideal for minimally invasive procedures. By reducing the trauma to the body compared to traditional open surgery, these instruments result in less pain, minimal scarring, and a significantly lower risk of complications. Surgeons benefit from enhanced precision, control, and visualization, enabling them to perform intricate procedures with exceptional accuracy, even in hard-to-reach areas. 

Additionally, the high degree of dexterity provided by robotic instruments allows for more delicate and effective interventions, particularly in complex cases. Moreover, minimally invasive procedures using robotic surgery come with a lower risk of complications. These procedures typically involve less blood loss, reducing the need for blood transfusions, and significantly decreasing the chances of infection. The smaller incisions also contribute to a reduced likelihood of scarring and other long-term issues, offering patients a quicker recovery and better overall outcomes.

Further, key Uterine Fibroids Treatment Devices market in the market are developing innovative devices for uterine fibroids treatment. For instance, in November 2022, Olympus launched the moresolutionTM Power Morcellator Tissue Extraction System, which includes the innovative PneumoLinerTM containment device and the moresolution Morcellator. This advanced system offers select patients a laparoscopic surgical option as an alternative to open hysterectomy or myomectomy for tissue removal. The PneumoLiner provides effective containment during the procedure, while the moresolution Morcellator is capable of cutting through dense or calcified fibroids.

Thus, the factors mentioned above are likely to boost the market segment and thereby increasing the overall Uterine Fibroids Treatment Devices market of uterine fibroids treatment devices across the globe.

North America is expected to dominate the overall uterine fibroids treatment devices market:

North America Uterine Fibroids Treatment Devices market is anticipated to hold the largest market share in the uterine fibroids treatment devices market in 2023. This dominance is primarily driven by the growing prevalence of uterine fibroids, an increasing demand for minimally invasive procedures, and heightened awareness leading to early diagnosis. Additionally, ongoing product innovations and frequent launches by key market players are significantly contributing to the Uterine Fibroids Treatment Devices market expansion in the region, positioning North America as a leader in the uterine fibroid treatment devices market.

According to the Society for Women's Health Research (2023), an estimated 15 million women of reproductive age in the United States experienced uterine fibroids. The growing prevalence of fibroids is driving the demand for uterine fibroid treatment devices, which offer significant advantages over traditional surgery, such as greater precision, smaller incisions, and faster recovery times. This shift towards minimally invasive procedures is further fueling Uterine Fibroids Treatment Devices market growth in the region.

Supporting this trend, data from the Centers for Disease Control and Prevention (2024), revealed that the age-adjusted percentage of women aged 18 and older who had undergone a hysterectomy was 14.6%, with the percentage increasing with age from 2.8% among those aged 18-44 to 41.8% among women aged 75 and older. 

Furthermore, the Office on Women's Health reported, that in 2022, nearly 500,000 women in the United States underwent hysterectomies each year. The growing preference for minimally invasive treatments as alternatives to more invasive procedures, such as hysterectomy, is a key factor contributing to the expansion of the uterine fibroids treatment devices market in North America.

Moreover, such increasing cases of uterine fibroids promote healthcare organizations to adopt advanced devices. For instance, in November 2022, Humber River Health (Humber) successfully integrated the Acessa ProVu® system into its treatment offerings, providing an innovative, minimally invasive solution for uterine fibroid management. This procedure enhances the hospital's service portfolio by offering a thorough and efficient treatment option for fibroids, distinguishing Humber as one of only two centers in Canada providing this advanced technology.

Additionally, technological advancements in product development by key Uterine Fibroids Treatment Devices companies are further accelerating the Uterine Fibroids Treatment Devices market growth. For instance, in September 2024, Gynesonics Inc., a medical device company specializing in minimally invasive solutions for symptomatic uterine fibroids, announced the launch of its SMART OS 2.4 software technology for the Sonata System. The Sonata System offers an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids, providing patients with a less invasive and highly effective alternative to traditional surgical procedures. Such technological advancements are fostering Uterine Fibroids Treatment Devices market growth.

Uterine Fibroids Treatment Devices Market Key Players: 

Some of the key Uterine Fibroids Treatment Devices companies operating in the uterine fibroids treatment devices market include Hologic, Inc., Merit Medical Systems, Insightec, Boston Scientific Corporation, Profound Medical, Olympus Corporation, Medtronic, Intuitive Surgical, KARL STORZ, Cook, The Cooper Companies Inc., Terumo Corporation, Stryker, CONMED Corporation, Minerva Surgical, Inc., Smith+Nephew, Momentis Innovative Surgery, Asensus Surgical US, Inc., Koninklijke Philips N.V., Johnson & Johnson Services, Inc., and others.

Recent Developmental Activities in the Uterine Fibroids Treatment Devices Market:

• In January 2025, Hologic, Inc. completed its acquisition of Gynesonics, Inc., gaining access to the Sonata System. This innovative technology combined real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to provide an incision-less, transcervical treatment for symptomatic uterine fibroids, including those linked to heavy menstrual bleeding.
• In October 2024, Caldera Medical acquired UVision 360, Inc., developer of the LUMINELLE® hysteroscopy and cystoscopy systems. This strategic acquisition enhanced Caldera Medical’s portfolio of minimally invasive solutions, particularly in advanced hysteroscopy, expanding its capabilities for diagnosing and treating conditions such as polyps, fibroids, and other intrauterine pathologies.
• In May 2024, Meditrina, a leader in women’s health medical devices, received FDA 510(k) clearance for its Gen 2 bipolar RF hysteroscopy system. This advanced system incorporates bipolar radiofrequency technology and introduced a new device, the Aveta Glo, marking a significant advancement in minimally invasive gynecologic procedures.

Key Takeaways from the Uterine Fibroids Treatment Devices Market Report Study

• Uterine Fibroids Treatment Devices Market size analysis for current uterine fibroids treatment devices market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key Uterine Fibroids Treatment Devices product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
• Key Uterine Fibroids Treatment Devices companies dominating the uterine fibroids treatment devices market.
• Various opportunities available for the other Uterine Fibroids Treatment Devices companies in the uterine fibroids treatment devices market.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current uterine fibroids treatment devices market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for uterine fibroids treatment devices market growth in the coming future?

Target Audience Who Can be benefited from this Uterine Fibroids Treatment Devices Market Report Study

• Uterine fibroids treatment devices product providers
• Research organizations and consulting companies 
• Uterine fibroids treatment devices related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in uterine fibroid treatment devices
• Various end-users who want to know more about the uterine fibroids treatment devices market and the latest technological developments in the uterine fibroids treatment devices market.  

Frequently Asked Questions for the Uterine Fibroids Treatment Devices Market:

1. What are uterine fibroids treatment devices?

• Uterine fibroids treatment device refers to medical equipment or technology used to treat uterine fibroids, which are non-cancerous tumors that develop in the uterus. These devices offer minimally invasive or non-invasive alternatives to traditional surgery, providing effective treatments that preserve the uterus and reduce recovery time.

2. What is the market for uterine fibroids treatment devices?

• The global uterine fibroids treatment devices market is estimated to grow at a CAGR of 8.57% during the forecast period from 2025 to 2032.

3. What are the drivers for the uterine fibroids treatment devices market?

• The demand for uterine fibroids treatment devices is being driven by the increasing cases of uterine fibroids, particularly among women of reproductive age, which is generating strong demand for effective treatment options. Simultaneously, greater awareness about the condition and improved access to healthcare are leading to earlier diagnosis, prompting timely medical intervention. Technological advancements have enabled the development of minimally invasive and more efficient treatment devices, enhancing patient outcomes and reducing recovery times. Furthermore, leading market players are actively investing in product development, introducing innovative solutions such as advanced ablation systems and robotic-assisted surgical tools. These factors collectively position the uterine fibroids treatment devices market for positive growth throughout the forecast period from 2025 to 2032.

4. Who are the key Uterine Fibroids Treatment Devices companies operating in the uterine fibroids treatment devices market?

• Some of the key Uterine Fibroids Treatment Devices companies operating in the uterine fibroids treatment devices market include Hologic, Inc., Merit Medical Systems, Insightec, Boston Scientific Corporation, Profound Medical, Olympus Corporation, Medtronic, Intuitive Surgical, KARL STORZ, Cook, The Cooper Companies Inc., Terumo Corporation, Stryker, CONMED Corporation, Minerva Surgical, Inc., Smith+Nephew, Momentis Innovative Surgery, Asensus Surgical US, Inc., Koninklijke Philips N.V., Johnson & Johnson Services, Inc., and others.

5. Which region has the highest share in the uterine fibroids treatment devices market?

• North America Uterine Fibroids Treatment Devices market is anticipated to hold the largest market share in the uterine fibroids treatment devices market in 2023. This dominance is primarily driven by the growing prevalence of uterine fibroids, an increasing demand for minimally invasive procedures, and heightened awareness surrounding early diagnosis. Additionally, ongoing product innovations and frequent launches by key uterine fibroids treatment devices companies are significantly contributing to the market's expansion in the region, positioning North America as a leader in the uterine fibroid treatment devices market.

Get detailed insights @ DelveInsight Blogs